申请人:TIANJIN BINJIANG PHARMA, INC.
公开号:US20140371278A1
公开(公告)日:2014-12-18
Disclosed are compound of formula (I) and pharmaceutically accepted salts and prodrugs thereof, wherein each of R
1
, R
2
, R
3
, R
4
, R
5
, R
6
, X
1
and X
2
is as defined in the description. These compounds are protein kinases inhibitors, especially the inhibitors of Mek, which are useful in the treatment of cancers and inflammation of mammals. Disclosed are the treatment methods of cancers and inflammation of mammals as well as pharmaceutical compositions comprising the compounds described herein. The preparation of benzoheterocyclic compounds are disclosed. Disclosed are the preparation of potential drug candidates, such as benzooxazol, benzothiazol, benzothiadiazol and the like.
本文披露了式(I)的化合物及其药用盐和前药,其中R1、R2、R3、R4、R5、R6、X1和X2中的每一个如描述中所定义。这些化合物是蛋白激酶抑制剂,特别是Mek的抑制剂,对哺乳动物的癌症和炎症的治疗有用。本文还披露了治疗哺乳动物癌症和炎症的方法,以及包括所述化合物的药物组合物。披露了苯杂环化合物的制备。还披露了潜在药物候选物的制备,如苯氧唑、苯噻唑、苯噻二唑等。